Labetalol Tillomed (Labetalol Hydrochloride)

Labetalol Hydrochloride blocks alpha‑1 adrenergic receptors, causing vasodilation, and simultaneously antagonizes non‑selective beta‑adrenergic receptors, reducing heart rate and contractility. The combined actions decrease peripheral vascular resistance and cardiac output, leading to lowered arterial pressure.

The appropriate dose of Labetalol Tillomed is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage adjustments are made according to clinical guidelines and individual therapeutic needs.

Safety of Labetalol in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Labetalol Tillomed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Labetalol’s unique dual action on alpha‑1 and beta receptors distinguishes it from pure beta‑blockers or calcium‑channel blockers. This profile offers effective blood pressure reduction with added vasodilatory benefit, making it useful in situations where rapid control is needed, such as hypertensive emergencies.

Labetalol Tillomed should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Labetalol Tillomed is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, heart block, acute heart failure, and marked hypotension that can lead to syncope. Patients should be monitored for signs of these conditions, especially during dose titration or when combined with other cardiovascular agents.

Labetalol is contraindicated in patients with known hypersensitivity to labetalol or any component of the formulation, severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and uncompensated heart failure. Caution is also advised in individuals with asthma or severe liver disease.